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Regulatory T cells constitute 5–10% 
of peripheral CD4+ T cells and play an 
essential role in the active suppression of 
autoimmune responses, in both humans 
and rodents. Increasing evidence suggests 
that CD4+ regulatory T cells that infil-
trate neoplastic lesions also play a signifi-
cant role in the suppression of antitumor 
immunity and may represent a key mech-
anism by which tumors foster immune 
privilege. Recently, a circulating subset 
of thymic-derived regulatory T cells that 
constitutively express FOXP3 as well as 
inducible costimulator (ICOS) and that 
inhibit T-cell proliferation by an interleu-
kin (IL)-10-dependent effect on antigen-
presenting cells (APCs) has been identified 
in healthy subjects.1 Of note, the survival, 
proliferation and immunosuppressive 
functions of these cells are strictly depen-
dent on ICOS-mediated, rather than on 
CD28-mediated, co-stimulation.1 Several 
studies have recently demonstrated that 
ICOS+FOXP3+ regulatory T cells abun-
dantly infiltrate several human neoplasms, 
including epithelial ovarian cancer 
(EOC),2 breast cancer,3 thyroid cancer4 
and melanoma.5 The intratumoral lev-
els of ICOS+FOXP3+ regulatory T cells 
were found to predict cancer progression 
more robustly than the abundance of all 
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tumor-infiltrating regulatory T cells,2,4 
indicating that this cell subset plays a key 
role in tumor-elicited immunosuppression 
(and hence in disease progression).
Plasmacytoid dendritic cells (pDCs), 
a rare subset of circulating dendritic cells, 
have also been detected in the microenvi-
ronment of many solid tumors. Whereas 
pDCs are known to participate in anti-
viral immunity as they respond to viral 
infections by producing high levels of 
Type I interferons (IFNs), the role of these 
cells within the tumor microenvironment 
has remained unclear. Tumor-infiltrating 
pDCs appear to maintain a non-acti-
vated state and generally do not produce 
Type I IFNs, reflecting either the lack 
of activation stimuli in situ or the active 
inhibition of pDC functions by malignant 
cells.6 Similar to high levels of regulatory 
T cells, abundant tumor infiltration by 
pDCs has also been associated with poor 
clinical outcomes,2,7 suggesting a potential 
link between pDCs and regulatory T cell-
mediated immunosuppression. Indeed, a 
role for pDCs in the activation and expan-
sion of regulatory T cells had been previ-
ously demonstrated in models of asthma, 
transplantation and oral tolerance.
But how do pDCs drive regulatory 
T cell-mediated immunosuppression in 
cancer? Tumor pDCs express high levels 
of the ICOS ligand (ICOS-L), along with 
low levels of CD80 and CD86,8 a unique 
constellation of co-stimulatory molecules 
that allows for the optimal stimulation of 
ICOS+ regulatory T cells.1 In fact, pDCs 
but not other APCs were found to stimu-
late the activation and expansion of ICOS+ 
FOXP3+ regulatory T cells by providing 
ICOS co-stimulation.2 Within tumor 
lesions, pDCs are located in the close 
proximity of ICOS+FOXP3+ regulatory 
T cells, and their abundance directly cor-
relates with that of this regulatory T-cell 
subset.2 Furthermore, independent stud-
ies have demonstrated that both pDCs 
and ICOS+ regulatory T cells constitute 
strong predictors of disease progression 
and poor clinical outcome in patients 
affected by ovarian,2 breast3 and thyroid 
cancer.4 Thus, pDCs promote immuno-
suppression by activating and expanding 
ICOS+FOXP3+ T regulatory cells through 
ICOS co-stimulation (Fig. 1). This signal-
ing pathway appears to be important for 
tumor progression as it directly influences 
the prognosis of patients bearing meta-
static cancers.
Although the ability of pDCs to stimu-
late ICOS+FOXP3+ regulatory T cells 
requires MHC-T-cell receptor (TCR) 
tumor-infiltrating plasmacytoid dendritic cells (pDCs) have been associated with poor patient prognosis. we have 
recently uncovered the ability of pDCs to activate and expand a subset of tumor-infiltrating FOXP3+ regulatory t cells 
that express inducible costimulator (ICOs), providing new insights into the mechanisms that govern the escape of cancer 
from immunosurveillance.
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directly recruits pDCs into the tumor 
microenvironment.6 In line with our 
model, inhibitors of CXCL12-CXCR4 sig-
naling axis have previously been shown to 
reduce tumor growth in mouse models of 
EOC.9,10 Finally, Toll-like receptor (TLR)7 
or TLR9 ligands could be used to promote 
robust antitumor immune responses by 
virtue of their capacity of activating pDCs 
to produce type I IFNs and of differentiat-
ing pDCs into cytotoxic effector cells.
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Taken together, these findings provide 
novel insights into the factors that medi-
ate cancer-elicited immunosuppression 
and identify new molecular targets for 
therapeutic interventions. In this setting, 
one therapeutic strategy would be to block 
ICOS-L/ICOS co-stimulation, to reduce 
the expansion and functions of ICOS+ reg-
ulatory T cells within the tumor microen-
vironment. Alternatively, the recruitment 
of pDCs into neoplastic lesions could be 
specifically targeted. EOC cells have been 
shown to produce large amounts of the 
CXCR4 ligand CXCL12 (also known as 
stromal cell-derived factor1, SDF1), which 
interactions, the nature of the antigen 
presented by pDCs is currently unknown. 
It is generally accepted that pDCs have a 
limited capacity to internalize exogenous 
antigens by phagocytosis and that they 
may rather be specialized in presenting 
endogenous molecules. However, tumor-
infiltrating pDCs were found to induce a 
strong expansion of ICOS+FOXP3+ regu-
latory T cells in cancer patients, raising the 
possibility that they also present tumor-
associated antigens (Fig. 1). Interestingly, 
a recent study has shown that pDCs are 
indeed able to take up exogenous tumor-
derived antigens via specific receptors.
Figure 1. role of plasmacytoid dendritic cells and ICOs+ regulatory t cells in tumor immunosuppression. Bone marrow-derived plasmacytoid den-
dritic cells (pDCs) and thymic-derived ICOs+FOXP3+ regulatory t cells are recruited from the circulation into the tumor microenvironment. tumor-
infiltrating pDCs express high levels of the ICOs ligand (ICOsL), which co-stimulates ICOs+FOXP3+ regulatory t cells in the context of tumor-associated 
antigen presentation by pDCs or bystander antigen-presenting cells (APCs). this drives the activation and proliferation of ICOs+FOXP3+ regulatory 
t cells, leading to a preferential accumulation of this regulatory t-cell subset within the tumor microenvironment. upon re-encounter with the tumor-
associated antigen, ICOs+FOXP3+ regulatory t cells secrete interleukin (IL)-10, hence suppressing the effector functions of tumor-specific CD4+ and 
CD8+ t cells. thus, the infiltration of neoplastic lesions by pDCs favors the establishment of an immunosuppressive microenvironment via the activa-
tion and expansion of ICOs+FOXP3+ regulatory t cells, de facto favoring disease progression.
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